Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.
about
Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndromeThe management of infertility associated with polycystic ovary syndromeIGF-1/IGFBP-1 increases blastocyst formation and total blastocyst cell number in mouse embryo culture and facilitates the establishment of a stem-cell lineTherapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome.Androstenedione response to recombinant human FSH is the most valid predictor of the number of selected follicles in polycystic ovarian syndrome: (a case-control study)Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation inductionProlonged gonadotropin stimulation for assisted reproductive technology cycles is associated with decreased pregnancy rates for all women except for women with polycystic ovary syndrome.Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile womenRecombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome.Clomiphene citrate--end of an era? A mini-review.Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial.Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction.Comparison between Unilateral and Bilateral Ovarian Drilling in Clomiphene Citrate Resistance Polycystic Ovary Syndrome Patients: A Randomized Clinical Trial of Efficacy.Polycystic ovary syndrome: chemical pharmacotherapy.Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility.Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome.Comparison of different starting gonadotropin doses (50, 75 and 100 IU daily) for ovulation induction combined with intrauterine insemination.Intraovarian arterial blood flow resistance in oligomenorrheal infertile women.Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrateTherapeutic options in the polycystic ovary syndrome.Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial.Current trends in the treatment of polycystic ovary syndrome with desire for children.Pharmacotherapy of ovarian hyperstimulation syndrome.Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach.Management of female infertility from hormonal causes.British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome.Ultra-low Doses of Follicle Stimulating Hormone and Progesterone Attenuate the Severity of Polycystic Ovary Syndrome Features in a Hyperandrogenized Mouse Model.Clinical outcomes of ovulation induction with metformin, clomiphene citrate and human menopausal gonadotrophin in polycystic ovary syndrome.Ovulation induction--optimizing results and minimizing risks.Recombinant follicle-stimulating hormone (follitropin alfa) versus purified urinary follicle-stimulating hormone in a low-dose step-up regimen to induce ovulation in Japanese women with anti-estrogen-ineffective oligo- or anovulatory infertility: reRecombinant follicle-stimulating hormone (follitropin alfa) for ovulation induction in Japanese patients with anti-estrogen-ineffective oligo- or anovulatory infertility: results of a phase II dose-response study.Live Birth after Rescue In vitro Maturation-intracytoplasmic Sperm Injection in Type 1 Diabetes, Polycystic Ovary Syndrome Patient Using Clomiphene-antagonist Protocol.Pilot study of the optimal protocol of low dose step‐up follicle stimulating hormone therapy for infertile women.
P2860
Q24188049-A80DD863-EC61-4A5E-AEA2-0486CFF53137Q24798425-910865B8-89E7-4E0B-A106-07764F76F739Q24805894-4993BA92-70B8-4A15-99BC-4D4456A89E15Q33230782-710B8892-6024-444D-880E-D0C30D17273FQ33667893-EE028B63-EE4C-4475-86D6-0BB78CFED38DQ33881072-A068E31E-F418-45F7-ACC3-48EC6F255690Q33897120-CDCBA49C-3EDF-4AF3-BAB2-C4980C387DF7Q34272037-BDB21FC7-D166-46C6-9308-60D98CE4129BQ34281880-311BABAF-7A11-4D6A-8240-1619DDCC5724Q34557430-6875458D-888C-4F11-B12B-1DA7B2B1E215Q35253410-A3431A79-EFE6-438F-B06C-0CCFD330EAB2Q35492219-C556CC2B-13B8-4FAB-8E28-1047B6D886A0Q35539042-5A535724-5897-49B4-8F8A-D7B457F8AA9FQ35639510-888C0081-2094-47D8-B306-0C94B51DB8E2Q35650609-388C1FC4-7C9B-4C59-B3F3-DAEA59CCD797Q36125610-51F1C9FE-F1DA-4C1D-B5F3-8F656A978D34Q36227590-CB53BB51-B536-4EC1-9D34-40236F1EE34FQ36268773-3293156D-8DE7-46E0-8ABA-ABB76CFB6A1EQ36663478-743DF1EF-D80B-46BF-BABD-F6905508A3DFQ36799800-343BBCB3-EC7A-4158-B52C-78D750871DE6Q36847973-25F6FB82-8F97-407E-9F9D-F3E698B5B25DQ37059302-18522995-A609-43ED-B401-03396A41B5ECQ37230319-C3A30F51-E839-4B44-9248-FC8559224874Q37790385-3BF1A54B-A406-43DD-B3A9-42B1642EE448Q37990857-DA084968-DAF7-4572-90F5-68B6950E6D0FQ38153916-07D550E0-CD4E-4569-BFE5-800C04E46D11Q38266109-603F34A2-6F2A-4381-AA9F-0EE0F47F079AQ42698614-974E1550-0069-4CD2-8C05-FECAA3EDC71FQ42868397-2E91747A-387E-4FAE-B6C5-207D70935977Q44517697-8D3E9AD7-0B82-41F0-A40E-BF0EA94B7791Q54962039-EB8999B0-3CF4-4E21-A27D-2DA29943ABFCQ55070527-FBDCD4FE-70C1-433F-87CE-3A201B0F259DQ55374801-1C5EE2F1-6DA6-45EE-B327-619F2DBF01C9Q55664512-E4BF457A-8CD9-4476-A5D2-F31694F4E34A
P2860
Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@ast
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@en
type
label
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@ast
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@en
prefLabel
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@ast
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@en
P356
P1476
Low-dose FSH therapy for anovu ...... , reflections and refinements.
@en
P2093
P304
P356
10.1093/HUMUPD/5.5.493
P577
1999-09-01T00:00:00Z